Evaxion (EVAX) Q2 FY26 earnings call

Evaxion reported significant operational momentum in Q2 FY26, marked by pipeline advancements and the launch of a new glioblastoma program, EVX-05, leveraging its AI Immunology platform. The company reaffirmed its cash runway into the second half of 2027, supported by disciplined resource allocation and the activation of an ATM facility. Management highlighted the recent positive Phase III results from a similar personalized cancer vaccine program by Moderna and Merck as a validation for the entire field, including Evaxion's EVX-01 program, which will present 3-year data at ESMO.